Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

<< Previous

Bullboard Posts

Next >>

Post by Joemareon Jan 25, 2024 11:18am

182 Views

Post# 35845039

Mr. Swiftly - can you give us your game plan?

Can someone find out what the game plan is:
a) do they have all of the answers? Or they need to do additoinal testing? THIS IS CRITICAL.
b) time line to respond - 30 days?
c) New date by FDA - 3 months after response? Less? More?

There is no need to wait for basic info until their shareholder meeting next month.

So so so so basic - can we get them to cough up some tangible answers.

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security